Viatris (HAM:VIA) Inventories, Raw Materials & Components: €1,271 Mil (As of Mar. 2026)


HAM:VIA Viatris Inc HAM:VIA
60 GF Score
Price €14.26
GF Value €9.62
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Viatris Inventories, Raw Materials & Components?

Viatris HAM:VIA +0.06% 60 Inventories, Raw Materials & Components is €1,271 Mil as of Mar. 2026. GuruFocus rates HAM:VIA with a GF Score™ of 60/100 and a GF Value™ of €9.62 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Viatris's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €1,271 Mil.

Viatris's quarterly raw materials declined from Sep. 2025 (€1,287 Mil) to Dec. 2025 (€1,215 Mil) but then increased from Dec. 2025 (€1,215 Mil) to Mar. 2026 (€1,271 Mil).

Viatris's annual raw materials increased from Dec. 2023 (€671 Mil) to Dec. 2024 (€1,285 Mil) but then declined from Dec. 2024 (€1,285 Mil) to Dec. 2025 (€1,215 Mil).

Viatris Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Viatris's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Inventories, Raw Materials & Components Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 816.32 539.50 670.97 1,285.34 1,214.73

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,331.35 1,341.60 1,287.12 1,214.73 1,271.38
HAM:VIA
60GF Score
Viatris Inc HAM:VIA
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €1,271 Mil mean?
Viatris (HAM:VIA) has a Inventories, Raw Materials & Components of €1,271 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Viatris and its competitors.
Is Viatris' Inventories, Raw Materials & Components too high?
Viatris' current Inventories, Raw Materials & Components is €1,271 Mil. Overall, Viatris has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Inventories, Raw Materials & Components compare to NBIX and UTHR?
Viatris' Inventories, Raw Materials & Components of €1,271 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Viatris and its competitors. Viatris's current Inventories, Raw Materials & Components is €1,271 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.62, compared to a current price of €14.26 — trading 48.3% above its estimated fair value. The current Inventories, Raw Materials & Components is €1,271 Mil. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Inventories, Raw Materials & Components is €1,271 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (HAM:VIA) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €14.26 is trading 48.3% above its estimated GF Value™ of €9.62. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for HAM:VIA:

  • Inventories, Raw Materials & Components: €1,271 Mil
  • GF Value™: €9.62 vs. price of €14.26 (48.3% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score

Get the complete analysis for HAM:VIA

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.26
Price
€9.62
GF Value